Merck R&D: A Jam-Packed Pipeline But Much Of It Wait-And-See
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the acquisition of Schering-Plough, Merck has one of the most robust pipelines in the industry, but after an R&D day May 11, much of the most interesting data is still yet to be seen.
You may also be interested in...
FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.
Merck Plans To Shed 13% Of Work Force By 2015
The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.
Merck Plans To Shed 13% Of Work Force By 2015
The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.